Cardinal Health (NYSE:CAH) Vs Danaher Corporation (NYSE:DHR) – Here’s The One Jim Cramer Said Did Better

Cardinal Health's (NYSE:CAH) shares have seen a significant increase of over 10% year-to-date but have experienced a decline of more than 8% since early September. In a September 15th appearance, Jim Cramer pondered whether the decline was a result of a shift towards AI stocks or the company's performance. Cramer noted that executives' responses indicated a strong rotation into various sectors, with Danaher (NYSE:DHR) being the only major company showing weakness.

He expressed skepticism about the downward trend, stating that Cardinal Health's recent quarterly performance was impressive, leading him to believe the decline was foolish. The company reported a profit per share of $2.91 during its fourth quarter earnings and set a 2027 profit per share guidance of $12.40 to $12.60, surpassing analyst expectations.

However, Cardinal Health's Q4 revenue of $63.67 billion did not meet the estimated $65.03 billion. The company's pharmaceutical business experienced a 21% profit growth, reaching $645 million. Despite a strong overall performance, Cardinal Health cautioned about potential challenges, including the Inflation Reduction Act's drug pricing charges and EPS normalization due to subsidies received in Q4.

Danaher Corporation (NYSE:DHR) has underperformed compared to Cardinal Health over the same period, with its shares dropping by more than 7%. The firm's second-quarter earnings were solid, but they deferred $100 million in revenue from Q2 and Q3 to fiscal 2027 and reduced the high end of its revenue growth forecast from 6% to 4%.

While Danaher's forward P/E ratio is higher than Cardinal Health's, it attracts more institutional investment, including hedge funds. However, short interest remains higher for Cardinal Health at 3.34% compared to Danaher's 1.54%.